SG and A included $1,800,000 of non cash related to stock options and other considerations issued under stock incentive plans. Operating loss was $7,800,000 $7,700,000 for each of the 2nd quarters of 2023 2022. Interest expense during the Q2 of 2023 was $5,600,000 Excluding accretion and other expense in connection with Series A preferred units and our Aemetis biogas subsidiary, compared to $6,700,000 during the Q2 of 2022. Additionally, our Aemetis Biogas subsidiary recognized $6,900,000 of accretion and other expenses in connection with preference payments on its preferred stock during the Q2 of 2023 compared to $1,500,000 during the Q2 of 2022. Net loss was $25,300,000 for the Q2 of 2023 compared to a net loss of $209,000 for the Q2 of 2022, including the impact in 2022 of a grant of $14,200,000 received from the United States Department of Agriculture, Biofuel Producer Program and the release of a litigation reserve of $1,900,000 Our India plant contributed $5,100,000 of adjusted EBITDA During the 3 months ended June 30, 2023, offset by adjusted EBITDA from the restart of the Keyes plant and other operations.